Drug ID:Drug115
Drug Name:Apixaban
CID:10182969
DrugBank ID:DB06605
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT03935451
Molecular Formula:C25H25N5O4
Molecular Weight:459.5 g/mol
Isomeric SMILES:COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
Synonyms:Apixaban; 503612-47-3; BMS-562247-01; BMS 562247-01; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; apixabanum; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; UNII-3Z9Y7UWC1J; 3Z9Y7UWC1J; CHEBI:72296
Phase 0: 5
Phase 1: 52
Phase 2: 52
Phase 3: 64
Phase 4: 57
Description:Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012.

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt960 10182969 Apixaban 2159 F10 Homo sapiens (human) None
dt961 10182969 Apixaban 2359 FPR3 Homo sapiens (human) Inhibitor
dt962 10182969 Apixaban 1577 CYP3A5 Homo sapiens (human) None
dt963 10182969 Apixaban 1066 CES1 Homo sapiens (human) None
dt964 10182969 Apixaban 2159 F10 Homo sapiens (human) 17914785 None
dt965 10182969 Apixaban 2147 F2 Homo sapiens (human) 17914785 None
dt966 10182969 Apixaban 338 APOB Homo sapiens (human) None
dt967 10182969 Apixaban 5447 POR Homo sapiens (human) None
dt968 10182969 Apixaban 2159 F10 Homo sapiens (human) Coagulation factor X inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03935451 Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease EARLY_PHASE1 RECRUITING McMaster University IBD|Venous Thromboembolism|Crohn Disease|Ulcerati… DRUG: Apixaban 2.5 milligram|DRUG: Placebo Oral T… Details
NCT04985968 The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis PHASE3 TERMINATED InDex Pharmaceuticals Ulcerative Colitis DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… Details
NCT06681181 A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants PHASE1 RECRUITING GlaxoSmithKline Colitis, Ulcerative DRUG: GSK4528287|DRUG: Placebo Details
NCT05992142 ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA PHASE4 COMPLETED Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW Ulcerative Colitis DRUG: 5-ASA Details
NCT00787202 A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… Details
NCT06321887 EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD PHASE3 RECRUITING Liverpool University Hospitals NHS Foundation Trust Inflammatory Bowel Disease|Iron Deficiency Anemia DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… Details
NCT00207688 A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients None COMPLETED Janssen Research & Development, LLC Ulcerative Colitis DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… Details
NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) PHASE2 TERMINATED Nektar Therapeutics Colitis, Ulcerative DRUG: LY3471851|DRUG: Placebo Details
NCT02958865 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… Details
NCT03943550 Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) PHASE1 TERMINATED Hoffmann-La Roche Ulcerative Colitis DRUG: RO7049665|DRUG: Placebo Details
NCT02840721 Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. PHASE2 COMPLETED Telavant, Inc. Colitis, Ulcerative DRUG: PF-06480605 Details
NCT04133194 Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis PHASE4 RECRUITING Flemming Bendtsen Ulcerative Colitis DRUG: Mesalazine|DRUG: Mesalazine Details
NCT01465763 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis PHASE3 COMPLETED Pfizer Ulcerative Colitis DRUG: tofacitinib|DRUG: Placebo Details
NCT06636656 A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis PHASE2 RECRUITING Boehringer Ingelheim Ulcerative Colitis DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… Details
NCT04996797 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) PHASE2 ACTIVE_NOT_RECRUITING Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Ulcerative Colitis DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… Details
NCT01458951 A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis PHASE3 COMPLETED Pfizer Ulcerative Colitis DRUG: tofacitinib|DRUG: Placebo Details
NCT04499495 Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea None COMPLETED Ferring Pharmaceuticals Ulcerative Colitis OTHER: PENTASA (mesalamine/ 5-Aminosalicylic acid… Details
NCT01959282 A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis PHASE2 COMPLETED Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… Details
NCT02318667 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). PHASE4 COMPLETED Merck Sharp & Dohme LLC Colitis, Ulcerative BIOLOGICAL: Golimumab Details
NCT00317356 A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis PHASE2 TERMINATED Otsuka Pharmaceutical Co., Ltd. Colitis, Ulcerative DRUG: OPC-6535(Tetomilast) Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S01 Anti-inflammatory inflammatory 5-Aminosalicylates (5-ASAs); corticosteroids Crohn's disease and ulcerative colitis are the two main com… Details
S02 Immunosuppression Classic immunosuppressive drugs azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus Ciclosporin-A and tacrolimus bind to specific intracellular… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

Apixaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis in Colorectal…

PMID: 40505290
Year: 2025
Relationship Type: Association Score: 6.5

INTRODUCTION: Guidelines recommend postoperative venous thromboembolism (VTE) prophylaxis in colorectal cancer patients, as well as others at high ri…

View Details
[Monotherapy using a direct oral anticoagulant (apixaban) for catheter thrombos…

PMID: 33177262
Year: 2020
Relationship Type: Treatment Score: 6.5

A 20-year-old woman with ulcerative colitis flare was admitted to Fukui Red Cross Hospital. During treatment with granulocyte and monocyte apheresis …

View Details